Literature DB >> 25401213

Chemotherapy-induced nausea and vomiting #285.

Nishant Tageja, Hunter Groninger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25401213      PMCID： PMC4268550          DOI： 10.1089/jpm.2014.9392

Source DB:  PubMed          Journal:  J Palliat Med        ISSN： 1557-7740            Impact factor:   2.947


× No keyword cloud information.
  19 in total

1.  Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study.

Authors:  F Roila; E Boschetti; M Tonato; C Basurto; S Bracarda; M Picciafuoco; L Patoia; E Santi; O Penza; E Ballatori
Journal:  Am J Clin Oncol       Date:  1991-06       Impact factor: 2.339

2.  Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.

Authors:  Kenneth C Lasseter; Jay Gambale; Bo Jin; Art Bergman; Marvin Constanzer; James Dru; Tae H Han; Anup Majumdar; Judith K Evans; M Gail Murphy
Journal:  J Clin Pharmacol       Date:  2007-05-24       Impact factor: 3.126

3.  Use of acupuncture in the control of chemotherapy-induced nausea and vomiting.

Authors:  Ting Bao
Journal:  J Natl Compr Canc Netw       Date:  2009-05       Impact factor: 11.908

4.  Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications.

Authors:  Olga Geling; Hans-Georg Eichler
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

Review 5.  Anticipatory nausea and/or vomiting.

Authors:  D Moher; A Z Arthur; J L Pater
Journal:  Cancer Treat Rev       Date:  1984-09       Impact factor: 12.111

Review 6.  Complementary medicine in palliative care and cancer symptom management.

Authors:  Patrick J Mansky; Dawn B Wallerstedt
Journal:  Cancer J       Date:  2006 Sep-Oct       Impact factor: 3.360

7.  Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence.

Authors:  J P Ioannidis; P J Hesketh; J Lau
Journal:  J Clin Oncol       Date:  2000-10-01       Impact factor: 44.544

8.  Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

Authors:  M G Kris; R J Gralla; R A Clark; L B Tyson; J P O'Connell; M S Wertheim; D P Kelsen
Journal:  J Clin Oncol       Date:  1985-10       Impact factor: 44.544

9.  Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

Authors:  P J Hesketh; S Van Belle; M Aapro; F D Tattersall; R J Naylor; R Hargreaves; A D Carides; J K Evans; K J Horgan
Journal:  Eur J Cancer       Date:  2003-05       Impact factor: 9.162

10.  A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis.

Authors:  K Jordan; A Hinke; A Grothey; W Voigt; D Arnold; H-H Wolf; H-J Schmoll
Journal:  Support Care Cancer       Date:  2007-01-05       Impact factor: 3.359
View more
  1 in total

Review 1.  Moxibustion for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis.

Authors:  Ziling Huang; Zongshi Qin; Qin Yao; Yuanxuan Wang; Zhishun Liu
Journal:  Evid Based Complement Alternat Med       Date:  2017-10-12       Impact factor: 2.629
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.